companydirectorylist.com  Global Business Directories and Company Directories
Search Business,Company,Industry :


Country Lists
USA Company Directories
Canada Business Lists
Australia Business Directories
France Company Lists
Italy Company Lists
Spain Company Directories
Switzerland Business Lists
Austria Company Directories
Belgium Business Directories
Hong Kong Company Lists
China Business Lists
Taiwan Company Lists
United Arab Emirates Company Directories


Industry Catalogs
USA Industry Directories












Company Directories & Business Directories

CURIS CONSULTING

ORLEANS-Canada

Company Name:
Corporate Name:
CURIS CONSULTING
Company Title:  
Company Description:  
Keywords to Search:  
Company Address: 6076 Voyageur Dr,ORLEANS,ON,Canada 
ZIP Code:
Postal Code:
K1C 
Telephone Number: 6138410327 
Fax Number:  
Website:
 
Email:
 
USA SIC Code(Standard Industrial Classification Code):
0 
USA SIC Description:
 
Number of Employees:
 
Sales Amount:
 
Credit History:
Credit Report:
 
Contact Person:
 
Remove my name



copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)









Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Your Subject:
Your Comment or Review:
Security Code:



Previous company profile:
CUSACK LAW OFFICES
CURVES FOR WOMEN
CURTIS, LESLIE
Next company profile:
CUMBRAE DANCE CTR
CUMBRAE SCHOOL OF DANCING THE
CUMBRAE DANCE CENTRE










Company News:
  • Home - Curis, Inc
    At Curis, we are developing differentiated therapeutics with the goal of improving the lives of cancer patients Our new animation shows how Emavusertib (CA-4948) is being developed to target hematologic malignancies and other cancers
  • Pipeline Overview - Curis, Inc
    We are focused on the development and commercialization of innovative therapeutics for the treatment of cancer * IP licensed from Aurigene ** IP licensed to Aurigene *** IP licensed to Genentech Indicates a program included in the Curis intellectual property portfolio, but not currently designated as a priority for clinical development
  • Company Overview - Curis, Inc
    At Curis, we apply this meaning to cancer, by developing novel therapies for slowing or preventing the progression of cancer and prolonging life – or closing and curi͒ng cancer
  • Emavusertib (CA-4948) - Curis, Inc
    As part of the collaboration with Aurigene, in October 2015, Curis exclusively licensed a program of orally-available, small molecule inhibitors of IRAK4 kinase, including emavusertib (CA-4948)
  • About - Curis, Inc
    We are a biotechnology company focused on the development of first-in-class and innovative therapeutics for the treatment of cancer Our clinical stage drug candidates are:
  • Curis Provides Third Quarter 2024 Business Update
    About Curis, Inc Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor
  • Curis Announces Additional Data from TakeAim Leukemia Study
    About Curis, Inc Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor
  • Partner Collaborations - Curis, Inc
    Curis’ collaborator Aurigene is one of the first companies to target inhibitory immune checkpoints using synthetic small molecule compounds that can be administered orally and result in potent immune-mediated anti-tumor activity thus far in the preclinical setting
  • Ahmed Hamdy, MBBCH - Curis, Inc
    Dr Hamdy is Chief Medical Officer of Curis, joining the Company in May 2025 Prior to joining Curis, he served as CEO and Chairman of the board of directors of Vincerx Pharma, Inc Prior to Vincerx, Dr Hamdy co-founded Acerta Pharma, LLC, and served as its CEO and CMO




Business Directories,Company Directories
Business Directories,Company Directories copyright ©2005-2012 
disclaimer